RxDoctor Payments Data

Halevoor Mahalingaiah, MD

Psychiatry · Vly Cottage, NYNPI 1598830804

Payments from drug & device makers

$1,817in general payments, 2019–2025

Across 22 payments — averaging $82.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$494
  • Otsuka America Pharmaceutical, Inc.$353
  • AbbVie$280
  • Sunovion Pharmaceuticals Inc.$193
  • E.r. Squibb & Sons, L.L.C.$128
  • Supernus Pharmaceuticals, Inc.$125
  • plus $244 from 3 others

What the payments were for

  • Food & beverage$1,78798%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,817 in reported general payments places this provider in the 80th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$9,046
Medicare patients
28
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate92$267,971
Abilify MaintenaAripiprazole84$212,651
IngrezzaValbenazine Tosylate20$163,603
Invega TrinzaPaliperidone Palmitate13$89,475
Austedo XrDeutetrabenazine12$64,819
VivitrolNaltrexone Microspheres12$19,747
RexultiBrexpiprazole11$16,500
Clozapine208$14,909
Aripiprazole88$6,288
Clozapine OdtClozapine29$5,976
Lurasidone Hcl21$4,329
Divalproex Sodium ErDivalproex Sodium87$4,032
Paliperidone ErPaliperidone40$3,163
Olanzapine108$1,624
Ramelteon15$1,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$353$229,15195 claims
Neurocrine Biosciences, Inc.Ingrezza$73$163,60320 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$494$64,81912 claims
Alkermes, Inc.Vivitrol$62$19,74712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Vly Cottage

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →